12:00 AM
Nov 24, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IMC-A12: Phase II started

ImClone began a U.S. Phase II trial to evaluate capecitabine and lapatinib with or without intravenous IMC-A12 in 154 patients who have progressed on trastuzumab-containing treatment. GlaxoSmithKline plc...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >